Avalo Therapeutics (AVTX) Research & Development (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Research & Development came in at $14.0 million in Q1 2026, up 53.97% YoY from $9.1 million in Q1 2025, and up 5.88% on a QoQ basis from $13.3 million in Q4 2025.
Avalo Therapeutics (AVTX) Research & Development (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Research & Development data on file, last reported at $14.0 million in Q1 2026.
- Quarterly Research & Development rose 53.97% year-over-year to $14.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.0 million (up 74.94% YoY) and the FY2025 annual result came in at $50.1 million, up 104.95% from the prior year.
- Research & Development improved to $14.0 million in Q1 2026, from $13.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $14.1 million in Q2 2025 to a low of $1.2 million in Q3 2023.
- A 5-year average of $7.9 million and a median of $8.2 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 2103.22% — and 2023, when it plunged 82.26%.
- Tracing AVTX's Research & Development over 5 years: stood at $6.2 million in 2022, then tumbled by 69.75% to $1.9 million in 2023, then jumped by 338.3% to $8.2 million in 2024, then surged by 62.13% to $13.3 million in 2025, then increased by 5.88% to $14.0 million in 2026.
- The last three Research & Development figures came in at $14.0 million (Q1 2026), $13.3 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | 23.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.42 Mn |
| Mar 31, 2026 | 14.05 Mn |
| Dec 31, 2025 | 13.27 Mn |
| Sep 30, 2025 | 13.62 Mn |
| Jun 30, 2025 | 14.07 Mn |
| Mar 31, 2025 | 9.12 Mn |
| Dec 31, 2024 | 8.18 Mn |
| Sep 30, 2024 | 9.54 Mn |
| Jun 30, 2024 | 4.60 Mn |
| Mar 31, 2024 | 2.12 Mn |
| Dec 31, 2023 | 1.87 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 4.66 Mn |
| Mar 31, 2023 | 6.01 Mn |
| Dec 31, 2022 | 6.17 Mn |
| Sep 30, 2022 | 7.04 Mn |
| Jun 30, 2022 | 8.51 Mn |
| Mar 31, 2022 | 9.58 Mn |
| Dec 31, 2021 | 11.51 Mn |
| Sep 30, 2021 | 10.55 Mn |